AC
IMVT icon

Aaron Cowen’s Immunovant IMVT Stock Holding History

Aaron Cowen’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-259,200
Closed -$12M – 118
2020
Q4 		$12M Sell
259,200
-276,084
-52% -$12.8M 0.17% 57
2020
Q3 		$18.8M Buy
535,284
+367,400
+219% +$11.1M 0.34% 46
2020
Q2 		$4.09M Buy
167,884
+131,784
+365% +$2.82M 0.09% 58
2020
Q1 		$562K Buy
+36,100
New +$543K 0.02% 61

Other funds holding IMVT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Aaron Cowen's IMVT Position: Q1 2021 in Review

Aaron Cowen sold out of Immunovant (IMVT) in Q1 2021, closing a stake of 259,200 shares — an estimated $12M sold.

Aaron Cowen first reported a position in IMVT in Q1 2020 and held it in 4 quarters. The position peaked at $18.8M in Q3 2020. 120 funds tracked by Wall St. Rank hold IMVT as of Q1 2021.

  • Aaron Cowen reported no remaining Immunovant position as of Q1 2021 after selling out during the quarter.
  • Aaron Cowen sold 259,200 Immunovant shares in Q1 2021, an estimated $12M.
  • Aaron Cowen first reported a position in Immunovant in Q1 2020 and held it in 4 quarters.
  • Aaron Cowen's Immunovant position peaked at $18.8M in Q3 2020.
  • 120 funds tracked by Wall St. Rank held Immunovant as of Q1 2021.

Based on Suvretta Capital Management's 13F filing for Q1 2021, filed 17 May 2021.